Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 2
1(50.0%)
2Total
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07539545Not ApplicableNot Yet Recruiting

The Comparison Between M-E-BCS and C-O-BCS.

Role: collaborator

NCT05900921Phase 2Unknown

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

Role: collaborator

NCT01758770Completed

China Action on Spine and Hip Status

Role: collaborator

All 3 trials loaded